Bristol Myers builds the case for psoriasis hopeful as it waits in regulatory limbo

Bristol Myers Squibb continues to tout more data for its experimental psoriasis drug that it hopes will shake up the market.

The pharmaceutical giant posted two-year results from a long-term extension study of deucravacitinib, showing the drug remained effective after two years. The drug, which analysts predict can bring in billions in sales by 2026, is an oral TYK2 inhibitor for adult patients with moderate to severe plaque psoriasis.

According to the latest data, clinical efficacy was maintained through up to two years of treatment, with response rates at week 60 of 77.7% and 58.7% for PASI 75, a measure of the disease’s severity. The safety profile also remained consistent and no new issues popped up.

Thursday’s results were consistent with the Phase III psoriasis trials, dubbed POETYK PSO-1 and POETYK PSO-2 posted in 2021. Bristol Myers may find it more difficult to expand into other indications, however, as the…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*